Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alligator Bioscience AB ( (SE:ATORX) ) has provided an announcement.
Alligator Bioscience has commented on Shanghai Henlius Biotech’s recent milestone of dosing the first patient in a U.S. Phase 3 trial for HLX22, a monoclonal antibody targeting HER2-positive gastric cancer. While not directly involved, Alligator stands to benefit financially from this development through potential revenue streams from milestones and royalties, as they hold a 35% entitlement from AbClon’s sublicense agreement with Henlius.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company focused on developing clinical-stage tumor-directed antibody drugs, particularly targeting the CD40 receptor. This approach aims to enhance T cell priming and counteract the immunosuppressive tumor microenvironment, offering potential benefits for cancer patients. The company’s lead candidate, mitazalimab, is advancing towards Phase 3 development, with promising results in metastatic pancreatic cancer.
YTD Price Performance: -74.02%
Average Trading Volume: 410,032
Current Market Cap: SEK190.3M
Learn more about ATORX stock on TipRanks’ Stock Analysis page.